Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2021

View Archived Issues

Phase I study evaluates PGV-001-based personalized multipeptide vaccines for prostate cancer

Phase I trial of molecular targeted therapy with adoptive cell therapy for DIPG and neuroblastoma

XRad initiates phase Ia study of XRD-0394 with radiation therapy in advanced solid tumors

Foghorn Therapeutics discovers SMARCA2/SMARCA4 inhibitors

Cannabinoid CB1/CB2 receptor partial agonists patented by Research Triangle Institute

BioTheryX presents PROTACs including casein kinase I isoform alpha degradation inducers

Stressed fat cells send mitochondria to teach heart cells self-defense

Landos collaborates with Johns Hopkins to further validate NLRX1 immunometabolic pathway in MS

MKK-4 inhibition for liver regeneration

Airway initiates phase Ib trial of AT-100 in mechanically ventilated patients with COVID-19

Chinese clearance for phase Ib/III trial of afuresertib with fulvestrant in HR+, HER- breast cancer

Pardes initiates phase I study of antiviral PBI-0451 for SARS-CoV-2 infection

Unnatural Products targets MDM2 and MDM4 with macrocylic peptides

Data presented for Sage Therapeutics' SAGE-718 for neurological diseases

First-in-human study planned with NXP-800 in advanced cancers

Preclinical studies characterize bispecific EGFR/CD16A NK innate cell engager AFM-24

RubrYc enters license and collaboration agreements on epitope-targeted antibody therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...